C-IRLRCoya Therapeutics
Treg-enhancing biologics, Treg-derived exosomes, Treg cell therapy
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-IRLR
C-IRLRC-IRLRTreg-enhancing biologics, Treg-derived exosomes, Treg cell therapy
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Every year, thousands of newborns suffer devastating brain injury during birth - and despite decades of research, there are still no approved drug therapies for Hypoxic Ischemic Encephalopathy (HIE). But one biotech company believes it may finally have a solution. Dr. Howard Berman, Ph.D. is Chief Executive Officer and Chairman of ReAlta Life Sciences ( https://realtalifesciences.com/ ), a clinical-stage biotechnology company developing novel therapies for severe inflammatory diseases. Dr. Berman brings a unique background spanning neuroscience, pharmacology, medical affairs, technology transfer, and biotech entrepreneurship. He earned his Ph.D. in Pharmacology and Neuroscience from Weill Cornell Medical College, where his research focused on pain and temperature processing in the human brain using functional MRI. Over the course of his career, he has held roles at Novartis, Eli Lilly and Company, and AbbVie, working across oncology, neuroscience, immunology, and business development
The ALSTARS trial will be conducted across 20-25 sites in the US and Canada, and will evaluate the safety and efficacy of an investigational treatment called COYA 302 for adults with Amyotrophic Lateral Sclerosis (ALS). COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. It is comprised of low dose interleukin-2 (LD IL-2) and DRL\_AB (a biosimilar candidate for abatacept). Participants will be randomly assigned to receive one of 2 regimens of COYA 302 or placebo (an inactive substance) in a 1:1:1 ratio for 24 weeks in the double-blind (DB) period. Those who complete this part of the study will be eligible to receive one of the two regimens of COYA 302 for an additional 24 weeks in a blinded active extension phase (EXT). The study will assess changes in disease progression using established ALS clinical outcome measures, including the ALS Functional Rating Scale-Revised (ALSFRS-R), neurofilament (NfL), maximal inspiratory pressure (MIP), slow vital capacity (SVC), and neurological assessments. Additional objectives include evaluation of biomarkers and safety through routine clinical assessments and adverse event monitoring.
What if you could slow down Alzheimer’s or ALS? That’s exactly the deeply personal journey Dr. Howard Berman, Founder and CEO at Coya Therapeutics, finds himself on. To day, Howard runs a mission-driven company that is making remarkable breakthroughs in the world of T-Cells. Driven by his father's personal battle with Dementia, Howard has embarked on a relentless quest for a cure. Along his journey, he uncovered an extraordinary technology devised by the brilliant Dr. Stanley Appel that gave him the courage to leave his last life in pharmaceuticals. In this episode, Dr. Berman speaks on the science of fear and the negative physical effects it can have on our bodies. Howard also gives listeners an educational crash course on what dementia is and the many ways it can rear its unfortunate, ugly head. It’s Berman to Berman on this episode of the Courageous Podcast.
Would you choose a sharp mind for 100 years or live to 200 in a stupor? 💡 Our latest episode of Founder CEO, hosted by Chris Salvi, dives into this with Howard Berman, the compassionate CEO of Coya Therapeutics. Discover his visionary insights and groundbreaking work in treating neurodegenerative diseases. Howard Berman leads @coyatherapeutics7911 , a Houston-based biotech company developing therapies that enhance regulatory T cells (Tregs) to combat neurodegenerative, autoimmune, and metabolic diseases. With innovative treatments like COYA 302 targeting ALS and Alzheimer’s, Coya's small team is making big strides in medical advancements. Don’t miss Howard’s heartfelt story and entrepreneurial journey. #entrepreneur #FounderCEO #FounderLife #StartupStruggles #CognitiveDecline #TherapeuticInnovation #fyp #inspired #ALS #alzheimer
Coya Therapeutics (COYA) is a clinical-stage company focused on developing multi-modality Treg therapies. CEO Howard Berman joins Nicole Petallides to give an overview of the company. He talks about how COYA’s leading candidate is Coya 302 and how the Alzheimer’s Drug Discovery Foundation invested $5M in COYA. Tune in to find out more about the stock market today. ======== Schwab Network ======== Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe Download the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185 Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7 Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watch Watch on Vizio - https://www.vizio.com/en/watchfreeplus-explore Watch on DistroTV - https://www.distro.tv/live/schwab-network/ Follow us on X – https://twitter.com/schwabnetwork Follow us on Facebook
Guest: Dr. Howard Berman CEO and Chairman of Coya Therapeutics $COYA Ticker: $COYA Website: https://coyatherapeutics.com/ Bio: Chief Executive Officer and Chairman of the Board Howard co-founded Nicoya Health in 2020 to realize the vision and research of Dr. Stanley Appel and merged the company with Coya Therapeutics in 2021 where he currently serves as Chairman and CEO. He has over 18 years of entrepreneurial and industry experience working at the interplay of science and business. His experience offers him a unique combination of business acumen and scientific credibility with the ability to assess, quantify, and bridge both disciplines. Howard gained corporate experience with increasing responsibilities and positions as a Medical Science Liaison at AbbVie where he spent 7.5 years launching Venetoclax in CLL and later, supporting numerous solid tumor assets. He also served in leadership roles at Novartis Pharmaceuticals and later Eli Lilly where he was the scientific point o
In this episode, Ayesha spoke with Howard Berman, PhD, Founder and CEO of Coya Therapeutics, a clinical-stage biotech company developing regulatory T cell (Treg) therapies targeting neurodegenerative, autoimmune and metabolic diseases. Dr. Berman founded Coya Therapeutics in 2021. Dr. Berman has over 18 years of entrepreneurial and industry experience working at the interplay of science and business. His experience offers him a unique combination of business acumen and scientific credibility with the ability to assess, quantify and bridge both disciplines. Dr. Berman gained corporate experience with increasing responsibilities and positions as a Medical Science Liaison at AbbVie where he spent 7.5 years launching Venetoclax in CLL and later, supporting numerous solid tumor assets. He also served in leadership roles at Novartis Pharmaceuticals and Eli Lilly. Dr. Berman received a Bachelor in Biology from the University of Michigan and a Masters and PhD in Neuroscience and Pharmacolo
Clinical-Stage Biotech Stock to Watch | Biotech Stock News Today | Coya Therapeutics | COYA Welcome to McNallie Money, your daily dose of Stocks, Investments and Personal Finance! Today we joined by the Chairman and CEO of Coya Therapeutics Inc., Howard Berman, ticker symbol COYA. Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous
Dr. Howard Berman, Founder/CEO of Coya Therapeutics, talks with Sully and Mike Costa about their breakthrough work with T-Cells and particularly T-Reg therapies. The T-Reg cell is the most critical mediator of inflammation. Coya Therapeutics is working to help autoimmune diseases with these Treg therapies. #bigbizshow #biztv #drhowardberman #coyatherapeutics #coya #t-regs #t-regtherapies #autoimmunedisease #inflammation #sully #mikecosta BizTV features compelling, fast-paced content that engages the audience in marketing, technology, and business innovations. A hip, fresh look at the game of business, BizTV empowers viewers to dive into entrepreneurship, the markets, investing, and travel. Watch full episodes: http://www.watch.biztv.com Learn more about BizTV: http://www.biztv.com Follow BizTV on Facebook: http://www.facebook.com/Biztelevision Follow BizTV on Twitter: http://twitter.com/biztv Follow BizTV on LinkedIn: https://nl.linkedin.com/company/biz-television
Howard Berman, CEO of Coya Therapeutics, a biotechnology company, had an interview with Jane King from Nasdaq on September 27, 2023. Howard shared the announcement about the acquisition of exclusive, global rights for a proprietary Exosome Engineering Technology from Carnegie Mellon University. This technology holds promise for diverse applications spanning neurodegeneration, autoimmune conditions, and oncology. Coya Therapeutics (NASDAQ: COYA) is a clinical-stage company focused on developing multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases. Website https://coyatherapeutics.com/ LinkedIn https://www.linkedin.com/company/coya-therapeutics/ Twitter https://twitter.com/CoyaTx Promoted by Quantum Media Group https://www.quantum-corp.com Coya Therapeutics is a client of Quantum Media. Quantum Media has partnered with Jane King, host of Innovators with Jane King show and reporter at Nasdaq, to interview our client, Coya Therapeutics. Jane King ha
Dr. Howard Berman, Founder/CEO of Coya Therapeutics, talks with Sully and Mike Costa about the power of T-regs and their medication that has the potential to slow down or stop autoimmune and metabolic diseases. #bigbizshow #biztv #drhowardberman #coyatherapeutics #coya #tregs #autoimmunedisease #als #metabolicdisease #sully #mikecosta BizTV features compelling, fast-paced content that engages the audience in marketing, technology, and business innovations. A hip, fresh look at the game of business, BizTV empowers viewers to dive into entrepreneurship, the markets, investing, and travel. Watch full episodes: http://www.watch.biztv.com Learn more about BizTV: http://www.biztv.com Follow BizTV on Facebook: http://www.facebook.com/Biztelevision Follow BizTV on Twitter: http://twitter.com/biztv Follow BizTV on LinkedIn: https://nl.linkedin.com/company/biz-television
Dr. Howard Berman and Dr. Stanley Appel have been working on a solution to neurodegenerative diseases like ALS, dementia, and Parkinson's disease for many years. As the Co-Founders of Coya Therapeutics, the pair have discovered these diseases are linked to inflammation in the brain and are currently overseeing a Phase 2 double-blind, placebo-controlled study at the Houston Methodist Hospital. Dr. Berman shares details on CW39 about the research and development of new therapies to enhance the function of the brain by modulating the body’s immune response. He also will speak how he was motivated to work in the field after caring for his father, a fellow doctor who suffered from debilitating dementia.
Jane King interviews Howard Berman, Ph.D., CEO & Chairman of the Board, Coya Therapeutics (NASDAQ: COYA). https://coyatherapeutics.com Innovators with Jane King profiles tech companies and thought leaders in the space. We're showing you a glimpse of the future. Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya’s product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platfor
Howard Berman, CEO of Houston-based Coya Therapeutics, appeared on KIAH's CW39 Houston show on June 9, 2023. In the interview, he tells his personal story which led to him founding Coya and developing treatments for dementia, ALS and Alzheimer's disease. Howard also shared how inflammation is a driver of neurodegenerative diseases and that Coya is at the forefront of showing how ramping up Tregs can slow or even stop disease progression based on their trials with Alzheimer's and ALS patients. ------------------------------------------------------------------------------------------------------------------ For more details you may check: Website https://coyatherapeutics.com/ Social Media https://www.linkedin.com/company/coya Promoted by Quantum Media Group https://www.quantum-corp.com/ Coya is a client of Quantum Media. Quantum Media has partnered with KIAH | CW 39 Houston to interview our client. KIAH | CW 39 Houston has given Quantum legal rights to upload this video anywhere in
Chris interviews the leaders of Coya Therapeutics, a pharmaceutical company based in Houston revolutionizing the push for effective neurodegenerative disease therapies. Coya went public with only five team members after working with world-renowned researcher and neurologist Stanley Appel to commercialize new therapies for neurological diseases in order to make them publically available. Dr. Howard Berman, the Founder and CEO of Coya, and Daniel Barvin, the Vice President of Operations and Patient Advocacy share the background of the company and where it’s heading.
Chris interviews the leaders of Coya Therapeutics, a pharmaceutical company based in Houston that is revolutionizing the push for effective neurodegenerative disease therapies. Coya went public with only five team members after working with world-renowned researcher and neurologist Stanley Appel to commercialize new therapies for neurological diseases in order to make them publically available. Join Chris Howard on this episode as he interviews Dr. Howard Berman, the Founder and CEO of Coya, and Daniel Barvin, the Vice President of Operations and Patient Advocacy, where they share the background of the company and where it’s heading. Timecoded Guide: [00:00] Start of Episode [01:00] Background of Coya [10:45] How the diseases are currently being treated [15:50] Current progress of ALS and Alzheimer’s therapy development [16:10] Process of IPO’ing and getting FDA approved [24:38] How a biologic therapy is manufactured [26:16] Being a med tech or bio company in Houston’s ecosyst
Coya CEO, Howard Berman, Ph.D., joined Gayle Guyardo on Bloom to discuss the role of #inflammation in #neurodegenerative diseases and share results from Coya's proof-of-concept open-label studies in both #ALS and #AlzheimersDisease.
Coya CEO, Howard Berman, Ph.D., Joined the Big Biz Show on May 25th, 2023 to discuss the role of dysfunctional #Tregs in #neurodegenerative diseases and share the exciting results from Coya's proof-of-concept open-label studies in both #ALS and #AlzheimersDisease.
Jane King interviews Howard Berman, Ph.D., CEO & Chairman of the Board, Coya Therapeutics (NASDAQ: COYA). https://coyatherapeutics.com Innovators with Jane King profiles tech companies and thought leaders in the space. We're showing you a glimpse of the future. Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya’s product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platfor
Like many of us, Howard Berman, Ph.D. has personal experience with the tragedy of cognitive decline. Neurodegenerative disorders are on the rise, and when one afflicted his father — a triple board-certified physician — he saw firsthand that they don't discriminate. Berman has dedicated his career to addressing neuro, autoimmune, and metabolic diseases, having founded Nicoya Health in 2020 and overseeing its merger with Coya Therapeutics the following year. The company came out of the gates this year fueled by an 11th-hour 2022 IPO, one of just a dozen on the year. Berman joined the Business of Biotech to share his strategy during a stingy stretch in biotech capital markets. #businessofbiotech #biopharma #biotech #cytiva http://cytiva.com/emergingbiotech Get notified when new episodes come out: https://www.bioprocessonline.com/bob Audio version available here: https://www.bioprocessonline.com/doc/funding-a-neurodegeneration-startup-with-coya-therapeutics-howard-berman-0001 Subscri
In this episode, VibeCast host Ray Dogum speaks with Howard Berman, PhD (Founder and CEO) and Daniel Barvin, MBA (VP of Operations and Patient Advocacy) from Coya Theraputics, about advancements in ALS and Alzheimer's therapies. Guest Info Howard Berman, PhD: Howard co-founded Nicoya Health in 2020 to realize the vision and research of Dr. Stanley Appel and merged the company with Coya Therapeutics in 2021 where he currently serves as Chairman and CEO. He has over 18 years of entrepreneurial and industry experience working at the interplay of science and business. His experience offers him a unique combination of business acumen and scientific credibility with the ability to assess, quantify, and bridge both disciplines. Howard gained corporate experience with increasing responsibilities and positions as a Medical Science Liaison at AbbVie where he spent 7.5 years launching Venetoclax in CLL and later, supporting numerous solid tumor assets. He also served in leadership roles at No
Welcome to Conversations Life Science Leaders Aren't Having. In this episode, we have the privilege of sitting down with Howard Berman, founder and CEO of Coya Therapeutics. Howard has had a distinguished career in big pharma, playing a pivotal role in the development and commercialization of billion-dollar drugs. However, his life took an unexpected turn when his father, Dr. Louis Berman, was diagnosed with dementia and rapidly declined. Howard witnessed firsthand the devastating impact of neurodegenerative diseases on patients and their families, which inspired him to use his expertise to make a difference. In our conversation, Howard shares his personal journey and the founding of Coya Therapeutics. He explains how his company is using cutting-edge science to develop therapies that tackle the underlying causes of neurodegenerative diseases, with a focus on improving patients' quality of life. We also gain insight into the challenges of drug development and the importance of stayi
Howard Berman, Ph.D., Chief Executive Officer of Coya Therapeutics, a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Tregs) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, presented a corporate overview at the Oppenheimer Rare & Orphan Disease Summit held virtually on May 21, 2021. Headquartered in Houston, TX, Coya Therapeutics™ is a clinical-stage biotechnology company developing first-in-class and best-in-class approaches utilizing adoptive regulatory T cells (Tregs) to target disease. The company’s CTreg™ (Cryopreservation for Tregs) system is patent pending and the first in the industry to overcome prior limitations of Treg cell therapies, allowing for serial infusions from a single manufacturing round. Through our proprietary TAI™ (Tregs Against Inflammation™) and patent pending iscEXO™ (immunosuppressive cell Exosome) platforms, Coya is focused on the advancement of disease
Howard Berman, Ph.D., CEO of Coya Therapeutics has a candid conversation with Mike Henson, co-founder of No More Excuses. Howard shares his journey from an executive at AbbVie to leading Coya in its quest to commercialize Dr. Stanley Appel’s regulatory T cell therapy for ALS and other neurodegenerative diseases.
MUST SEE interview for all ALS patients! Dr. Howard Berman of COYA therapeutics discusses his journey from AbbVie Pharma to his incredible involvement with Dr. Appel's Regulatory T cell therapy "TREGS" for ALS. If you have ALS, this one is a most watch! For much more info on this TREG procedure and other exciting videos about ALS please go to: https://youtu.be/Tqh2pks-xkg Dr. Appel's video credit: @EverythingALS Join the fight for access to new ALS drugs at www.facebook.com/groups/nomoreexcusesals Please follow @als_now on Twitter for the latest commentary on ALS access and activism.
Coya Therapeutics CEO Dr. Arun... - Pharmaceutical Daily Facebook Log In Pharmaceutical Daily's Post Pharmaceutical Daily January 20 · Shared with Public Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan. Dear Fellow Stockholders, Coya enters 2026 with strong momentum and a clear sense of
%PDF-1.4 %���� 1 0 obj > endobj 2 0 obj > stream ����JFIF��(ICC_PROFILEmntrRGB XYZ acsp���- desc�trXYZdgXYZxbXYZ�rTRC�(gTRC�(bTRC�(wtpt�cprt� �|�cN!h�iEͿ��=�լ.�qK���b~#b+h�L��H͕����ܨ���˓��f�T�� rA;ZiJ*��M����}3�1 3�ƪCm2�� ��_�H�⟙���:��'n���~�c�����8��7md {ƿ�9�=�t���i� r>x��U) Hj j�e��R۪Oe.�~� �X�!hl���y *8}��-�����h���i�� 9g!ãD�)��2���n�����£ Wm�Sk�˗���.?��w��]� �������|JQ'�h��S�1=��.um*�T[�ڞq�8 @����G���ODg�0�:l� ��YDG n� D�5�KU1�v2q]@�Ҳz�Q������&%����%��T��Rˊd���|�� |���ū(�Ӵ�9T��J Ԛ�L�)�2e%sC�{��@�_I Y +pN�9 [r��B�ObQ"D & … >> endobj 253 0 obj > >> endobj 254 0 obj > >> endobj 255 0 obj > stream EO.Pdf application/pdf EO.Pdf 19.1.40.0 endstream endobj 256 0 obj > stream HLinomntrRGB XYZ � 1acspMSFTIEC sRGB���-HP cprtP3desc�lwtpt�bkptrXYZgXYZ,bXYZ@dmndTpdmdd��vuedL�view�$lumi�meas $tech0 rTRC ELRY`gnu|���������������� &/8AKT]gqz������������ !-8COZfr~���������� -;HUcq~������
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Coya's Approach to Neuroinflammation with Arun Swaminathan | Coya Therapeutics, Inc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or … rom playing it safe. We invest in the ideas others might overlook. Our Ignition Fund injects funding to unexpected breakthroughs, fast. Because real change happens when bold thinking meets action. By backing bold research, our supporters are giving hope where it’s needed most - and pushing the boundaries of what’s possible. Read the full article by Dr David Cox, PhD in The Telegraph today (subscription may be required) ⤵️ https://lnkd.in/e3uAQTMe 70 1 Comment Like Comment Sha … rom playing it safe. We invest in the ideas others might overlook. Our Ignition Fund injects funding to unexpected breakthroughs, fast. Because real change happens when bold thinking meets action. By backing bold research, our supporters are giving hope where it’s needed most - and pushing the boundaries of what’s possible. Read the full article by Dr David Cox, PhD in The Telegraph today (subscription may be required) ⤵️ https://lnkd.in/e3uAQTMe 9 Like Comment Share Copy Lin
Our CEO Arun Swaminathan presented at the H.C. Wainwright & Co., LLC Annual Global Investment Conference today on the latest updates from the company and our therapies. You can listen to the full… | Coya Therapeutics, Inc. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your
ALS Clinical Trials and Research | For those that recently had questions about Coya’s next ALS trial…
coya's treasures - Sacramento - California - United States - Eventeny Skip to content or footer Organize Event Management Tools Event mapping Ticketing / registration Artist, vendor & exhibitor management Volunteer management Sponsor management Event programming & talent management - New Interactive schedules Hardware solutions Mobile app for organizers - New Solutions by event type About Eventeny Product overview Company values Pricing Helpful Resources Knowledge base Community center Comparison guide Blog Contact sales Product updates Case studies See all events Create an Event Part … keting text messages. Reply STOP to cancel, HELP for help. Msg & data rates may apply. Newsletter coming soon. In the meantime, browse new events. Subscribe Go to participant sign-up Browse events Eventeny was founded on the belief that managing large-scale events with hundreds of exhibitors, vendors, sponsors, and volunteers should not be stressful and burdensome. Our mission is to remove event organizers from being the 5th most stressful job in the world. That's why we buil
Coya Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Coya Therapeutics, Inc. Public Company | 2020 | Texas, United States | < 10 | NASDAQ: COYA | www.coyatherapeutics.com Public Company | 2020 | Texas, United States | < 10 | NASDAQ: COYA | www.coyatherapeutics.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Endocrinology and Metabolic Disease Other Diseases Nervous System Diseases Exosomes In … pawning multiple therapeutic products based on fundamental discoveries by Nobel Prize Laureates and other world-class scientists from top universities. The investment management team's strong track record in combination with the novel scientific discoveries the team has identified are really exciting." "I have spent time diligencing 28 Capital's platform and the science behind it, and I believe deeply in its potential to create a lasting impact on the future of medicine. 28 C … Arts and Sciences and has been the recipient of the ASCO Distinguished Service Award. Dr. Norton has served on or chaired numerous committees of the National Cancer Institute, National Institutes of Health, and the Institute of Medicine of the National Academy of Sciences. Dr. Norton has supported the development of major pharmaceuticals, including Herceptin and Enhertu, which he shepherded from the earliest stages through the FDA process and into commercialization. 28 Capit … Institute (Houston, TX) with funding from The Peggy and Gary Edwards Endowment Fund. Study patients received subcutaneously administered CTLA4-Ig, followed by a 5-day course of low-dose IL-2 every four weeks, for a total of 22 weeks of dosing and follow-up. The study aims to enroll up to 10 patients, and these interim results include data from the first 5 patients with mild to moderate FTD who have completed the full course of treatment. Dr. Arun Swaminathan, Coya’s Chief Ex … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view ful
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Coya Therapeutics Reports Fiscal Year 2025 Financial Results and Updates on Neurodegenerative Disease Clinical Programs - GeneOnline News Skip to content Advertise Inquiries | About Us | | Events Subscribe Intelligence Menu Toggle Markets & Deals Policy & Regulation Ranking & Reports Founders’ Circle Development to Market Discovery Menu Toggle R&D Frontiers Trials & Approvals CDMO & CRO Activity Public Health Oncology Insights Infection, Immunity & Vaccination Nexus Menu Toggle AI, Tech & Digital Innovation Advanced Biologics & Biosimilars Exosomes &am
All Coya Therapeutics articles | Drug Target Review Your browser is not supported Sorry but it looks as if your browser is out of date. To get the best experience using our site we recommend that you upgrade or switch browsers. Find a solution Skip to main content Skip to navigation Site name Site name Mast navigation Become a member Sign In Search our site Search our site Search Menu Close menu Home News Oncology AI Topics Back to parent navigation item Topics Technology Resources Diseases Drugs and therapies Research and development Tools and techniques Business Webinars Whitepapers Reports
Who owns COYA THERAPEUTICS INC? Top stakeholders of COYA according to 13F filings - stockzoa stockzoa Fund Directory 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X-Z Upgrade to Premium Login Javascript is disabled or is not supported by your browser. Please upgrade your browser or enable Javascript to navigate the interface properly. Who owns COYA THERAPEUTICS INC? Add alert for COYA Ticker: COYA CUSIP Number: 22407b108 Tip: Access positions for across all investors Analyze quarterly positions in Coya Therapeutics with up to 7 years of data, all consolidated into one spreadsheet Download … Coya Therapeutics stock Who bought or sold COYA THERAPEUTICS INC this quarter? Fund or Company Name Shares Held Valued At Change in Shares As Of Actions Historical COYA THERAPEUTICS INC position of DME Capital Management Source: stockzoa.com " data-trend_url="/ticker/coya/trend/dme-capital-management-lp/"> DME Capital Management 2.3M $9.2M 15% Mar 2026 Add alert View chart Historical COYA THERAPEUTICS INC position of AIGH Capital Management Source: … View chart Historical COYA THERAPEUTICS INC position of Dimensional Fund Advisors Source: stockzoa.com " data-trend_url="/ticker/coya/trend/dimensional-fund-advisors-2/"> Dimensional Fund Advisors 96k $378k 205% Mar 2026 Add alert View chart Historical COYA THERAPEUTICS INC position of Morgan Stanley Source: stockzoa.com " data-trend_url="/ticker/coya/trend/morgan-stanley/"> Morgan Stanley 86k $338k 61% Mar 2026 Add alert … 6 Add alert View chart Who sold out of Coya Therapeutics? Fund or Company Name Date Sold Shares Held Valued At AWM Investment Company Dec 2025 725k $4.2M Dauntless Investment Group Sep 2025 153k $872k Walleye Trading Advisors Dec 2025 37k $215k OMERS Administration Corporation Dec 2025 35k $200k Trexquant Investment Dec 2025 25k $145k Prosperity Wealth Management Sep 2025 24k $136k Millennium Management Dec 2025 21k $12 … r punitive damages. Past performance is a poor indicator of future performance. Fund Directory: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X-Z
#ftd #endftd #coyatherapeutics #neurodegenerative | Coya Therapeutics, Inc. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agree
Coya Therapeutics - Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results Skip to main content Skip to main content Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analyst Coverage Financials SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Composition Resources Information Request Form Investor Email Alerts Investor Contacts News Details Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analyst Coverag … pbell, Professor of Biomedical Engineering at CMU, presented a proof-of-concept application of the licensed exosome engineering technology, “Rapid Functionalization of Treg Exosomes for Targeted Immunotherapy” at the 5th Exosome Based Therapeutic Development Summit in Boston, MA The presentation can be accessed here . Coya and CMU entered into a Research Collaboration Agreement and Option Agreement in 2022 to develop a unique patented technology intended to advance the potent … olled Phase 2 data of LD IL-2 in AD, expected by summer 2024. We also intend to submit an IND application for a randomized double-blind placebo-controlled Phase 2 trial in ALS in 1H 2024. Further, we anticipate publishing multiple peer reviewed publications during this time related to blood biomarker findings in the prior LD IL-2/CTLA4Ig proof of concept clinical trial, as well as clinical data findings for LD IL-2 in AD,” concluded Dr. Berman. Anticipated Events and Mileston … didates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates,
Coya Therapeutics - Coya Therapeutics Reports Additional Proof-of-Concept Clinical Biomarker Data in Patients with Alzheimer’s Disease Skip to main content Skip to main content Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analyst Coverage Financials SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Composition Resources Information Request Form Investor Email Alerts Investor Contacts News Details Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Sto … didates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates,
Coya Therapeutics to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Alzheimer’s Association International Conference (AAIC) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Sub … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Lone Star Bio Coya Therapeutics to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Alzheimer’s Association International Conference (AAIC) June 28, 2023 | 7 min read Twitter LinkedIn Facebook Email Print Coya Therapeutics … didates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, … when you subscribe to GenePool! MORE ON THIS TOPIC Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-to-find-out" > Antibody-drug conjugate Can ADCs be kinder and gentler? Join BioSpace at BIO to find out June 23, 2026 ·&n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
--> Coya Therapeutics Secures Option Agreement for Exclusive Worldwide Rights to Exosome Engineering Technology from Carnegie Mellon University --> Login Start Free Trial Catalyst Calendar FDA Calendar Track key readouts and FDA decision dates in biotech and pharma. BPW Portfolio Bio Hedge Fund Shots and more... Historical FDA Calendar Review past FDA decisions and clinical readouts. Market Movers Track today's biotech market movers Biotech Earning Calendar Stay updated on biotech earnings. Historical PDUFA Dates Review past PDUFA dates and decisions. PDUFA Calendar Stay ahead of upcoming PDUF … p; past IPOs. Bio Pharma Screener Catalyst Sync™ Track biotech catalysts. Hedge Fund Screener Analyze hedge fund holdings. Company Screener Holistic company & pipeline analysis. All Stocks Holdings Explore hedge fund stock data. Heat-Map Market size & sector heat map. Inside Trades Monitor insider trading. Biotech Analyst Ratings Biotech analyst ratings & price targets M&A Tracker Track M&A deals and acquisition targets Resources News Latest biotech news.
FDA Grants Fast Track Designation to Coya Therapeutics’ COYA 302 for ALS Treatment - GeneOnline News Skip to content Advertise Inquiries | About Us | | Events Subscribe Intelligence Menu Toggle Markets & Deals Policy & Regulation Ranking & Reports Founders’ Circle Development to Market Discovery Menu Toggle R&D Frontiers Trials & Approvals CDMO & CRO Activity Public Health Oncology Insights Infection, Immunity & Vaccination Nexus Menu Toggle AI, Tech & Digital Innovation Advanced Biologics & Biosimilars Exosomes & Delivery Precision Medicines Cell,
Coya Therapeutics - Events & Presentations Skip to main content Skip to main content Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analyst Coverage Financials SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Composition Resources Information Request Form Investor Email Alerts Investor Contacts Events & Presentations Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analyst Coverage Financials SEC Filings Governance Governance Documents Exe
Life Biosciences presents ER-300 and ER-100 data at Aging Meeting | David A. Sinclair A.O., Ph.D. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue t … or add a comment, sign in Noah Cockroft 8mo Report this post This year’s Nobel Prize in Physiology or Medicine honored the discovery of regulatory T cells (Tregs) -the immune system’s “peacekeepers.” While no Treg-based therapies are approved yet, biotech leaders like Sonoma Biotherapeutics and Coya Therapeutics are rapidly advancing clinical programs targeting autoimmune and neurodegenerative diseases. SonomaBio’s engineered Tregs are showing promise in rheumatoid arthritis … k 8mo Report this post On October 6, 2025, the Nobel Assembly awarded the Nobel Prize in Physiology or Medicine to Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their discoveries around peripheral immune tolerance — specifically, the role of regulatory T cells (Tregs) in preventing the immune system from attacking the body’s own tissues. The Nobel spotlight on regulatory T cells (Tregs) reinforces momentum in immunology, oncology, and transplant medicine—but industry
Arun Swaminathan Discusses Coya's Immune-Based Approach to Neurodegenerative Disease | Coya Therapeutics, Inc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By cl
COYA - Annual Local Government Conference Affiliates Sponsors & Exhibitors Business Meeting Resources Registration Agenda Travel Hotel and Travel FAQs Forms Contact Registration Agenda Hotel and Travel FAQs Forms Affiliates Sponsors Business Meeting Resources Contact Apply Now Celebrating 75 Years of Local Government – Shaping the Next 75 The Alaska Municipal League (AML) is excited to host the 2025 Conference of Young Alaskans (COYA), to be held in conjunction with our 75th Annual Local Government Conference this December in Anchorage. In celebration of the Alaska Municipal League’s 75th … nable to financially support your participation, scholarships may be available. Apply Now! Key Details Dates: December 8-12, 2025 Location: Dena’ina Center, Anchorage, Alaska Costs Covered: Conference registration Deadline to Apply: November 7, 2025 by 11:59 PM Eligibility and Selection Delegates must be nominated by AML member municipalities and selected for their interest in public service, civic engagement, and community leadership. Your local government sponsor will … any support. For more information, contact Hannah Atkinson at [email protected] . Apply Now Complete and submit this form to apply for the 2025 Conference of Young Alaskans, which will take place December 8-12, 2025, at the Dena’ina Center in Anchorage. © 2026 Alaska Municipal League Annual Local Government Conference All rights reserved.
COYA Stock Price, News & Analysis | Coya Therapeutics --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & Gas Defens … Food and Drug Administration (FDA) accepted its Investigational New Drug (IND) application for COYA 302 for the treatment of FTD. In addition, Coya reported results from an investigator-initiated open-label study in patients with FTD using low-dose IL-2 and CTLA4-Ig, which are the components of COYA 302. In that study, Coya reports enhanced Treg numbers and suppressive function and cognitive stability over a 22-week treatment period, with no serious adverse events observed. … nt under the same agreement. Acceptance, without objection, of a Clinical Trial Application (CTA) by Health Canada for COYA 302 in ALS, allowing activation of Canadian clinical sites. FDA acceptance of an IND for COYA 302 in FTD, enabling planned clinical evaluation in that indication. These events are documented in Coya’s Form 8-K filings and press releases, which also note that COYA 302 remains an investigational product not yet approved by the FDA or any other regulatory a
Coya Therapeutics - Investor Relations Skip to main content Skip to main content Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analyst Coverage Financials SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Composition Resources Information Request Form Investor Email Alerts Investor Contacts Investor Relations Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analyst Coverage Financials SEC Filings Governance Governance Documents Executive Manag
ALS Clinical Trials and Research | New Trial Posted:
Contra Costa County Office of Education - California Opportunity Youth Apprenticeship (COYA) skip to main content Contra Costa County Office of Education Home Board Employee Intranet Schools Contra Costa County Office of Education Contra Costa Intranet Our Schools Find A School or Browse All Schools Submit QUICK LINKS Elementary Schools Middle Schools High Schools https://www.cccoe.k12.ca.us/Departments--Schools/Departments/Student-Programs/Youth-Services-YS/Workforce-Programs/California-Opportunity-Youth-Apprenticeship-COYA/ Translate Chinese Dutch English French German Greek Italian Japanese … uguese Russian Spanish Vietnamese Tagalog Khmer Farsi Hindi Punjabi Search Site Submit About CCCOE About Annual Report 2019-2020 Annual Report English 2019-2020 Annual Report Spanish 2018-2019 CCCOE Annual Report Contact Us History https://www.cccoe.k12.ca.us/About-CCCOE/Superintendent/Previous-Superintendents/index.html Education Facts & Statistics Land Acknowledgement Maps & Directions Meeting Rental Information Organizational Chart Staff Directory Strategic Plan Strategic … reliminary Administrative Services Credential Program (PASC) PASC Admission and Application Clear Administrative Credential Program (CACP) 2023 Red Cohort Preconditions Submission Assessment, Research & Evaluation Data Visualizations California Distinguished Schools Program Curriculum and Instruction English Learner/Title III Technical Assistance English Learner Roadmap Resources Bilingual Coordinators Network Resources CA Dept of Ed Resources LCAP (Local Control and Accounta
Ann Lee, Ph.D., SVP at Bristol Myers Squibb, Joins Coya Therapeutics™ Board of Directors - Coya Therapeutics Skip to content Home About Us Clinical Trials Science & Technology Pipeline Investor Relations Resources Patient Resources Contact Ann Lee, Ph.D., SVP at Bristol Myers Squibb, Joins Coya Therapeutics™ Board of Directors HOUSTON, June 01, 2021 (GLOBE NEWSWIRE) — Coya Therapeutics, Inc. (Coya™), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Tregs) and Treg-derived exosome therapeutics for neurodegenerative a
Milan Kalawadia and Arun Swaminathan on COYA 302 ALS treatment | Ben Comer posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you
EX-10 2 coya-ex10_1.htm EX-10.1 EX-10   CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”.   LICENSE AND SUPPLY AGREEMENT   This License and Supply Agreement (“ Agreement ”) is made as of the 1 st day of April 2023 (the “ Effective Date ”), by and between: Coya Therapeutics Inc. , a company registered under the … products. C. The Parties desire to enter into this Agreement wherein DRL shall grant a license to use the Product to Coya, to enable Coya to further develop and Commercialize the Final Product in its designated territories in the manner to be set forth in this Agreement, and whereas Coya shall grant a license to the developed Final Product to DRL for it to Commercialize the same in its designated territories in the manner to be set forth in this Agreement.   NOW, THEREF … cGMP and cGLP, (ii) all laws, ordinances, codes, rules and regulations as they apply to the Product and the Final Product, and (iii) those applicable to the development, manufacturing, import, offer to sell, sale, distribution, use, marketing or promotion of the Product and the Final Product or any aspect thereof and the obligations of Parties hereunder, as the context requires under this Agreement.   “ Application ” means the Dossier filing before the Reg … ii) the corporate entity’s shareholders approve and complete any plan or proposal for the liquidation or dissolution of the entity. 2       “Commercialization” means the marketing, promotion, distribution and sale of the Final Product(s) developed hereunder, any and all activities that relate to the marketing, promoting, distributing, importing or exporting for sale, offering for sale, and selling of such Final Product (including pre-launch … int ownership, license or otherwise), other than pursuant to this Agreement, to grant, without violating the terms of any agreement with a Third Party, a license, access or other right in, to or under such IP or Know-How or materials. Notwithstanding anything in this Agreement to the contrary, if a Party has undergone a Change in Control and is a
Coya Therapeutics - Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100 Skip to main content Skip to main content Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analyst Coverage Financials SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Composition Resources Information Request Form Investor Email Alerts Investor Contacts News Details Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analyst Coverage Financials SEC Fi … minathan, Ph.D. currently Coya’s Chief Business Officer and incoming CEO. “This award recognizes Howard and his significant accomplishments in the life science industry.” PharmaVoice 100 honorees are selected from a pool of nominations submitted by readers and colleagues, evaluated by the PharmaVoice team, and then categorized into 10 distinct groups: Standout Leaders, Cancer Care Visionaries, Cardiometabolic All-Stars, Trailblazers, Biotech Pathfinders, Rare Disease Warriors … didates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates,
Molecules and Minerals | Coya Therapeutics CEO on Novel ALS & FTD Treatment, Phase 2 Trials | Arun Swaminathan LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign … cal results are successful as hoped for, there is a possibility that Coya could submit an application to the FDA for accelerated approval for COYA-302 in the treatment of ALS later in 2027. No guarantees of course. My interview with Coya's CEO Arun Swaminathan is found at the link below. Please follow me on my podcast Molecules and Minerals. I also wish to acknowledge production assistance by my daughter Elyssa Carroll Goldman . Molecules and Minerals | Coya Therapeutics CEO
An ALS treatment wave is approaching, and this biotech CEO is ready to surf | PharmaVoice Skip to main content CONTINUE TO SITE ➞ Don't miss the most important voices in pharma Let PharmaVoice's free newsletter keep you informed on what industry leaders are saying, straight from your inbox. By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | BioPharma Dive Xtelligent Pharma Life Sciences Explore our brands An Informa TechTarget Publication Voices Q&A Profiles Biotech Spotlight First 90 Days Opinions To … to see if there's additional non-relative money, either through partnerships or grant money to continue to strengthen our cash position and extend our runway as well, without a need to go back to investors anytime soon. What would you say is the biggest challenge for you as a new CEO? It’s what probably most CEOs have in small biotechs — to keep us focused, keep us advancing towards our primary objectives, keep the company well funded, and make sure that we have the resources
Arun Swaminathan: Coya CEO on ... - Biotech 2050 Podcast - Apple 播客 搜索 主页 新发现 排行榜 搜索 2025年11月20日 37 分钟 Arun Swaminathan: Coya CEO on Neuroinflammation, BD Strategy & Patient-Driven Biotech Biotech 2050 Podcast 播放 Synopsis: In a conversation rich with strategic insight, Coya Therapeutics CEO Arun Swaminathan unpacks the intersections of scientific innovation, business development discipline, and capital-efficient execution that define today’s most resilient biotechs. With a 25-year foundation spanning R&D, clinical pharmacology, marketing, and BD, Arun offers investors a rare systems-le
--> Coya Therapeutics' CEO Arun Swaminathan discusses the company's focus on harnessing T-regs to treat neurodegenerative diseases top of page Home Quick Takes Around Kendall Science Spotlight BiotechTV U Company News Bright Minds Shows Biotech Direct BioVenture VoiCes Biotech CEO Sisterhood The Studio at Kendall Square Off-Target Effects with Matt Gline Tech + Tours Coya Therapeutics' CEO Arun Swaminathan discusses the company's focus on harnessing T-regs to treat neurodegenerative diseases Mar 27 1 min read He describes the science behind Coya's combination therapies, and prog
Coya Therapeutics - Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer Skip to main content Skip to main content Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analyst Coverage Financials SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Composition Resources Information Request Form Investor Email Alerts Investor Contacts News Details Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analyst Coverage … didates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates,
Press Release Archives - Page 5 of 6 - Coya Therapeutics Skip to content Home About Us Clinical Trials Science & Technology Pipeline Investor Relations Resources Patient Resources Contact Category: Press Release Coya Therapeutics to Host Key Opinion Leader Webinar on ALS001 for the Treatment of Amyotrophic Lateral Sclerosis -Featuring Stanley H. Appel, M.D., internationally renowned researcher and neurologist- -Webinar to be held Friday, June 11, 2021 at 11:30 a.m. ET- HOUSTON, June 02, 2021 (GLOBE NEWSWIRE) — Coya Therapeutics, Inc., (Coya™), a clinical-stage biotechnology company
Coya Therapeutics™ Announces the Appointment of Anabella Villalobos, Ph.D. to its Board of Directors - Coya Therapeutics Skip to content Home About Us Clinical Trials Science & Technology Pipeline Investor Relations Resources Patient Resources Contact Coya Therapeutics™ Announces the Appointment of Anabella Villalobos, Ph.D. to its Board of Directors HOUSTON, May 25, 2021 (GLOBE NEWSWIRE) — Coya Therapeutics, Inc. (Coya™), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Tregs) and Treg-derived exosome therapeutics
Coya Therapeutics - Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases Skip to main content Skip to main content Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analyst Coverage Financials SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Composition Resources Information Request Form Investor Email Alerts Investor … didates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates,
Press Releases & News from Houston Biotech Coya Therapeutics Skip to content Home About Us Clinical Trials Science & Technology Pipeline Investor Relations Resources Patient Resources Contact Resources Blog The Forest Fire Behind Neurodegenerative Diseases June 28, 2021 My Personal Journey to a Cure for ALS June 7, 2021 A Serendipitous Moment April 28, 2021 Scientific Publications Tregs and Neurodegenerative Disease The role of regulatory T cells in neurodegenerative diseases The role of regulatory T cells in nervous system pathologies The Trojan horse – neuroinflammatory impact
Houston Biotech Company Targeting Treg Dysfunction Skip to content Home About Us Clinical Trials Science & Technology Pipeline Investor Relations Resources Patient Resources Contact Pipeline Pioneering Treg-Targeted Therapies Our broad pipeline combines three therapeutic modalities targeting Treg dysfunction: Treg modifying biologics, allogeneic Treg-derived exosomes, and autologous Treg cell therapy. COYA 302 Program Additional Pipeline Assets We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells. We ar
Coya Therapeutics - Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock Skip to main content Skip to main content Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analyst Coverage Financials SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Composition Resources Information Request Form Investor Email Alerts Investor Contacts News Details Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analyst Coverage Fina
Multi-modality Treg Enhancing Therapies Skip to content Home About Us Clinical Trials Science & Technology Pipeline Investor Relations Resources Patient Resources Contact Science & Technology We are Pioneering the Research and Development of New Therapies to Enhance the Function of Regulatory T Cells (Tregs) Dr. Shimon Sakaguchi , a member of our Scientific Advisory Board, discovered Tregs in 1995. Dr. Stanley Appel , the Chair of our Scientific Advisory Board , and the research team at Houston Methodist Hospital leveraged this discovery by developing transformative therapies enhancin
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Coya Therapeutics - Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results Skip to main content Skip to main content Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analyst Coverage Financials SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Composition Resources Information Request Form Investor Email Alerts Investor Contacts News Details Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analyst Coverage Financi … osing patients across ~25 clinical sites in the U.S. and Canada. Clinical Trial Application (CTA) acceptance from Health Canada to proceed with the COYA 302 ALSTARS Phase 2 trial in Canada. Announced COYA 302 ALS trial acceptance by NEALS as a NEALS-affiliated trial. Announced U.S. FDA acceptance of Investigation New Drug (IND) Application for COYA 302 for the treatment of frontotemporal dementia (FTD). Reported results of the investigator-initiated study of low-dose IL-2 and
Coya Therapeutics - Coya Therapeutics, Inc. Announces Expansion of Exclusive Worldwide Licensing Agreement with ARScience Biotherapeutics, Inc. for Development and Commercialization of COYA 301, Coya’s Low-Dose Interleukin 2 (IL-2) Product Candidate Skip to main content Skip to main content Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analyst Coverage Financials SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Composition Resources Information Request Form Investor Email Alerts Investor … didates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates,
%PDF-1.4 % ���� 3 0 obj > /PageLabels > ] >> /Outlines 2 0 R /Pages 1 0 R >> endobj 4 0 obj > endobj 5 0 obj > >> endobj 6 0 obj > stream x��[[� G^)o��7��@Τ���R^@ 8�1$D(�[a�����O���wgzwڷ8�:>�=[g���_U�����n��u��������� �k*����3n�O�Pr*Ζ ��� /����xz8}�C�No����ǟ��������W����~>�����n������ ��9L��Xʬ8��i�~)�\欓�5K�C�$����t�=�)�2;��L.� �G/�}��z�"˺�F����l�^�+�RC�ˤ%�w� �U��c �B �SHd`�S�:�?�S1� kL):��9�� �K�~^6�)N�A.h2O�| s������)RXl�� {(�H!�4 )�&�R�Ef �d��,Ue�%�kƉa�%�4�b$㧒 T�7� � ���8��9a����:%�l��9�j�d�H�8���u ��ϑ�T�@8 � '��� �_�W��L )r��$�# �Q�J�=�t�Vh#P�?�h�= … ���/�Q����:���/�Qq��+ӵ �{�{Y��˓꧰��]����K��`�)�������z�h��+[�_k���I�ݹrFp��G����=�|��+���x#�E�?� ���{^�� ��^��&������-�S˅3�rN2ry>椞$��He]�ȥg`��4W���'��ϗ�E�t�}*�h�6� .�|�8!I �ǚQEMim5��p[Fd�C�Qށ�^��x"�&�/����2U;�=Oc��tm1QTi��U 3 ��1��'��h � ���� L��u���_��O�ze⹊/��y8��zc鏭c�h��@�ѝL�d�� *t� C�q��ǠA^����,���W�W��'�E�/� ��� ����?��'��k���5���?��'��k��QE (��=ʲ��߰ :Vm����&_h���$��Z��|G�� ��� R(������b��.m��:U��������[~�:��m;�2�d� �Ì�Bx8��z� … ���/�Q����:���/�Qq��+ӵ �{�{Y��˓꧰��]����K��`�)�������z�h��+[�_k���I�ݹrFp��G����=�|��+���x#�E�?� ���{^�� ��^��&������-�S˅3�rN2ry>椞$��He]�ȥg`��4W���'��ϗ�E�t�}*�h�6� .�|�8!I �ǚQEMim5��p[Fd�C�Qށ�^��x"�&�/����2U;�=Oc��tm1QTi��U 3 ��1��'��h � ���� L��u���_��O�ze⹊/��y8��zc鏭c�h��@�ѝL�d�� *t� C�q��ǠA^����,���W�W��'�E�/� ��� ����?��'��k���5���?��'��k��QE (��=ʲ��߰ :Vm����&_h���$��Z��|G�� ��� R(������b��.m��:U��������[~�:��m;�2�d� �Ì�Bx8��z�
Insurtech startup Luko acquires Coya and gains insurance license | Insurtech Insights News & Insights Conferences Europe USA Asia Webinars Insurtech Rankings Future50 Americas Future50 Europe Resources Reports Success Stories Menu News & Insights Conferences Europe USA Asia Webinars Insurtech Rankings Future50 Americas Future50 Europe Resources Reports Success Stories Insurtech startup Luko acquires Coya and gains insurance license Insurtech startup Luko acquires Coya and gains insurance license French startup Luko is acquiring German startup Coya in order to grow its European presen … lity, dog liability and bike insurance. Source: Tech Crunch Share this article: APPLY TO SPONSOR Gain access to the most senior audience of insurance executives, entrepreneurs, and investors. We offer a wide range of opportunities for you to engage with our attendees from networking to thought leadership. Sponsorship packages provide a wide range of opportunities developed for almost any budget and are designed to help achieve your branding, networking, and/or thought leaders … Business Function Underwriting Claims Distribution Strategy / Leadership Phone Submit Insurtech Insights 123 Buckingham Palace Rd, London, SW1W 9SH [email protected] Insurtech Insights is world’s largest insurtech community, connecting industry executives, entrepreneurs and investors. Linkedin Play Solitaire Home America Europe Asia We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By c
COYA-201 - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 COYA-201 Last update 08 May 2025 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Exosomes Synonyms Target - Action modulators Mechanism Immunomodulators Therapeutic Areas Immune System Diseases Nervous System Diseases Endocrinology and Metabolic Disease Active Indication Autoimmune Diseases Metabolic Diseases Neurodegenerative Diseases Inactive Indication - Origi … l Therapy Autologous IV Administration COYA 101 for ALS: Initiate Phase 2b with grant funding or collaborative partnership (2024). Financial Results (Unaudited) As of December 31, 2022, Coya had cash and cash equivalents of $5.9 million compared to $4.3 million as of December 31, 2021. As previously announced, on January 3, 2023, Coya closed its IPO and on January 25, 2023, the underwriters’ exercised their over-allotment option. Coya received aggregate net proceeds of $14.5 … didates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, … t hopes instead to get other funding to push it forward — either in the form of grant money or a partnership. In the S-1, it projected that the Phase IIb trial would now come in 2024. The biotech started when AbbVie vet, now Coya CEO, Howard Berman took interest in Houston Methodist Hospital’s Stan Appel’s Treg research, licensing it in October of 2020. Including a $10 million Series A from February of 2021, the biotech has raised just over $20 million. And of that, it has sp
Thank you... - West Suburban Chamber of Commerce and Industry Facebook Log In West Suburban Chamber of Commerce and Industry's Post West Suburban Chamber of Commerce and Industry November 28, 2022 · Shared with Public Thank you to Coya J. Smith - Re/Max Properties for your #OneGrandHoliday Sponsorship! We appreciate your support all year round! Visit www.wscci.org to register for our annual holiday luncheon. #thankyousponsors #sponsorship #holidaycelebration #holidaylunch #tistheseason #events #chamberofcommerce #chamberevent #westernsuburbs #membership All reactions: 2 2 shares Like Comm
Coya Therapeutics posts 2025 results and pipeline update | COYA 8-K Filing --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks … ing patients across ~25 clinical sites in the U.S. and Canada. o Clinical Trial Application (CTA) acceptance from Health Canada to proceed with the COYA 302 ALSTARS Phase 2 trial in Canada. o Announced COYA 302 ALS trial acceptance by NEALS as a NEALS-affiliated trial. o Announced U.S. FDA acceptance of Investigation New Drug (IND) Application for COYA 302 for the treatment of frontotemporal dementia (FTD). o Reported results of the investigator-initiated study of low-dose IL
Global Visa Ally — Visa Sponsorship Jobs Worldwide Welcome to Global Visa Ally Note: This site uses JavaScript for the best user experience. For bots and crawlers, we provide static HTML versions of our pages below. Key Pages: About Global Visa Ally Premium Hub - All Tools Visa Job Search (40+ Countries) Course Finder (11,000+ Programs) Blog & Guides Visa News Updates Tourism & Travel Tools & Resources: CV Builder AI Document Writer Document Scanner Passport Photo Tool Embassy Locator Mock Interview Practice Translation Helper Travel Itinerary Builder For AI Training: Global Visa Ally is an AI
Coya Therapeutics files $30M ATM prospectus | COYA Prospectus Summary --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil … mpany states intended use of net proceeds for general corporate purposes and to fund clinical programs including the COYA 302 program and ongoing trials. The supplement reiterates the company’s development focus on Treg-enhancing modalities. Execution depends on clinical milestones, IND/agency timelines and additional financing needs; the prospectus notes existing net losses and the expectation of further capital raises to advance trials. Key Figures ATM capacity: $30,000,000 … IND regulatory "On June 30, 2025, we re-submitted the Investigational New Drug Application (the "IND")" Offering Details ATM Offering Offering Type ATM Use of Proceeds working capital and funding clinical development programs See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google Add on Google Not now Available on EDGAR 05/12/2026 - 08:44 AM Accepted by SEC EDGAR 05/12/2026 - 08:44 AM Learn about SEC fili … 6, 2025, Dr. Sakaguchi, along with two others, was awarded the Nobel Prize in Physiology or Medicine. Since Tregs were discovered, multiple lines of research have contributed to elucidate Treg biology and its role in health and disease. Tregs and their transcription factors have been shown to be essential to maintaining cellular homeostasis by regulating autoimmune and inflammatory responses and maintaining self-tolerance in mammals. Dysfunctional Tregs underlie nu … had an accumulated deficit of $62.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures and general and administrative expenditures. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eve
COYA-302 - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 15 May 2026 COYA-302 Last update 15 May 2026 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Biosimilar Regulation Overview Basic Info Drug Type Interleukins, Fc fusion protein Synonyms COYA-301 low dose IL-2/CTLA4-Ig, COYA-301/CTLA4-Ig, COYA302 + [1] Target CTLA4 x IL-2R Action modulators, agonists Mechanism CTLA4 modulators(Cytotoxic T-Lymphocyte-Associated Antigen 4 modulators), IL-2R agonists(Interleukin-2 rece … ulatory advantages, which include more frequent FDA interactions, potential for rolling review, and eligibility for expedited programs such as Accelerated Approval and Priority Review. “We are pleased to announce that COYA 302 has received FDA Fast Track designation for the treatment of ALS,” said Arun Swaminathan, Ph.D., Chief Executive Officer of Coya. “This recognition underscores the devastating nature of ALS and the urgent need for new therapies. At Coya, we remain fully … et medical needs. Announced U.S. FDA acceptance of Investigation New Drug (IND) Application for COYA 302 for the treatment of frontotemporal dementia (FTD). Reported results of the investigator-initiated study of low-dose IL-2 and CTLA4-Ig combination treatment demonstrating Treg enhancement and cognitive stability in FTD patients. Announced $11.1 million private placement, led by Dr. Reddy’s Laboratories, Inc. ($10 million) and Greenlight Capital ($1.1 million), an existing
%PDF-1.6 %���� 398 0 obj >stream hެVMOI�+}Eh�{f�Ȓ�K�Cv7-�"ƞ8#۲�����{�=�8D eE���Uկ���y��r�)W��^y[CUj�/FÓ�c��V�_�g�N��~[���v����.G�Y����ax5��U�s�ou������ �*�Шm��ݭ)-��)u�&�t���B�/���uޯ|^g��?��U��� ����o>���vu�S�xu�W� ���ɧ�]�V��j�.�+�k�ɠ]6�}�����)�|�0��~'�x���3�Th6�M7�V|?�ݛ�/���t�Ά�ŲQ��t��_���z�iĔ�ٶ�n�-��g� 9���������x���>j�����x�i�)�2�椏 wxg�x�1/ܥs�O�7���IK8�� ��� Q4�wF��T0^�`M�Z+B�ֹZ����]�&q]�|�- ���� 9���� `��T^�> w��# ���O�R b�|��һЦb���z��i�'6���04,p")���7|;0���F��!��u�\�pF�E�D����aC��`���,uT%��|A�G�&��P����F=��¼�Y�C�s��_�X�T�I�/}]�ca�H] … 021-03-31T16:16:39-08:00 2021-04-09T14:06:16-08:00 Acrobat PDFMaker 21 for Word application/pdf Portland Highbaugh uuid:5aaf8a57-376b-4d4a-82cc-0832357b62f6 uuid:83b4fcd5-b8ec-437b-94c8-db5f0a660cc5 Adobe PDF Library 21.1.177 endstream endobj 331 0 obj >/Metadata 107 0 R/OCProperties >>>/Outlines 198 0 R/Pages 328 0 R/StructTreeRoot 210 0 R/Type/Catalog>> endobj 335 0 obj >stream H��hy�����5���À0*0�U endstream endobj 336 0 obj >stream H�LV{lS�?�����\�ľ��}�$��_��t �I��
Coya Therapeutics, Inc. Financial Disclosures & SEC Filings — TradingView Search Products Community Markets Brokers More EN Get started Markets / USA / Stocks / Health Technology / Biotechnology / COYA / Documents Coya Therapeutics, Inc. COYA Nasdaq Stock Market COYA Nasdaq Stock Market COYA Nasdaq Stock Market COYA Nasdaq Stock Market Market closed No trades No trades Overview Financials News Documents Community Technicals Forecasts Seasonals Options ETFs More SEC filings and other documents Explore the latest company documents and SEC filings from the company, including Forms 10-K, 10-Q,
Raven.config('https://[email protected]/147999').install(); InnovationMap X Startups Tech Health Energy Impact Money Lifestyle Space Sports Featured Innovators Guest Columns Houston Voices Houston Innovation Awards Promoted Advertise Subscribe INNOVATIONMAP EMAILS ARE AWESOME Sign up now About Us Advertise Submit a Story Terms of Use Privacy Policy Startups Tech Health Energy Impact Money Lifestyle Space Sports Featured Innovators Guest Columns Houston Voices Houston Innovation Awards Promoted Advertise Subscribe Houston biotech co. raises $11M to advance ALS drug deve … s disease. The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026. Coya was founded in 2021. The company merg … ress by bringing back our Scaleup of the Year category for the second year. The award honors an innovative later-stage startup that's recently reached a significant milestone in company growth. Six breakthrough businesses have been named finalists for the 2025 award. They range from climatetech startups to a biotech company developing new drugs for neurodegenerative diseases and more. Read more about these businesses and their impressive growth below. Then join us at the … Coya, founded in 2021, received FDA acceptance for its investigational new drug application for COYA-30 this summer. It closed its IPO in January 2023 for more than $15 million and added $26 million in PIPE funding that same year. Last year, the company secured an additional $15 million in PIPE funding. Fervo Energy Houston-based Fervo Energy is working to provide 24/7 carbon-free energy through the development of cost-competitive geothermal power. The company is developing i … ous illnesses last year. Koda Health was founded out of the TMC's Biodesign Fellowship in 2020 by CEO Tatiana Fofanova, chief medical officer Dr. Desh Mohan, and chief technology officer Katelin Cherry. The company raised a $7 million series A earlier this year, and also announced major partnerships and integrations with Epic, Guidehealth, Me
%PDF-1.4 %���� 1 0 obj /Creator /Title /Author /Subject /Keywords /CreationDate /ModDate >> endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj > endobj 5 0 obj > endobj 6 0 obj > endobj 7 0 obj > /Font > >> /MediaBox [0 0 612 792] /Contents 76 0 R /StructParents 1 /Parent 3 0 R /CropBox [0 0 612 792] /Group > /Annots [77 0 R 79 0 R 80 0 R 81 0 R 83 0 R 85 0 R 87 0 R 89 0 R 91 0 R 93 0 R 94 0 R 109 0 R 111 0 R 112 0 R 113 0 R 114 0 R 115 0 R 116 0 R 117 0 R] >> endobj 8 0 obj > /Font > >> /MediaBox [0 0 612 792] /Contents 78 0 R /StructParents 2 /Parent 3 0 R /CropBox [0 0 612 792] /Group > >> en
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
COYA SEC Filings - Coya Therapeutics, Inc. 10-K, 10-Q, 8-K Forms --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & Gas … an $11.1 million January 2026 private placement, and management expects this to fund operations into the second half of 2027. As a key pipeline milestone, the FDA granted Fast Track Designation to lead ALS candidate COYA 302. Rhea-AI Impact Rhea-AI Sentiment End-of-Day 2.63% Tags quarterly report - 05/12/2026 07:41 AM Filing Coya Therapeutics (NASDAQ: COYA) posts Q1 loss as COYA 302 wins FDA Fast Track Rhea-AI Summary Coya Therapeutics reported a Q1 2026 net loss of $7.2 mill … an $11.1 million January 2026 private placement, and management expects this to fund operations into the second half of 2027. As a key pipeline milestone, the FDA granted Fast Track Designation to lead ALS candidate COYA 302. Rhea-AI Impact Rhea-AI Sentiment End-of-Day 2.63% Tags quarterly report - 05/12/2026 07:39 AM Filing Fast Track lifts Coya Therapeutics (NASDAQ: COYA) Q1 2026 biotech update Rhea-AI Summary Coya Therapeutics reports first-quarter 2026 results and highlig … $4.53 Rhea-AI Summary Coya Therapeutics, Inc. director Mark H. Pavao received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $4.53 per share, expire on April 9, 2036, and will vest 100% on the first anniversary of the grant date, subject to continuous service. Rhea-AI Impact Rhea-AI Sentiment End-of-Day 10.22% Tags insider - 04/09/2026 06:42 PM Filing New Coya Therapeutics (COYA) director Mark H. Pavao files initial Form … , effective April 1, 2026, with a term running to the 2028 annual meeting and a grant of options to purchase 10,000 shares vesting after one year, alongside standard non‑employee director compensation. Rhea-AI Impact Rhea-AI Sentiment End-of-Day -1.72% Tags current report - 03/23/2026 12:15 AM Filing [EFFECT] Coya Therapeutics, Inc. SEC Filing Rh
10-Q Q2 false 0001835022 --12-31 15,221,308 0001835022 2024-01-01 2024-03-31 0001835022 coya:InitialPublicOfferingAndOverAllotmentOptionMember 2023-01-01 2023-03-31 0001835022 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2024-04-01 2024-06-30 0001835022 us-gaap:PrivatePlacementMember us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001835022 us-gaap:RetainedEarningsMember 2022-12-31 0001835022 coya:PatentKnowHowAndLicenseAgreementMember srt:ScenarioForecastMember 2025-01-01 2025-01-01 0001835022 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringM … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” … development. Substantial additional financing will be needed by the Company to fund its operations and to commercially develop its product candidates. No assurance can be given that any such financing will be available when needed or that the Company’s research and development efforts will be successful. The Company follows the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 205-40, Pre … cash equivalents of $ 36.6 million , which is expected to enable the Company to fund its operating expenses and capital expenditure requirements into 2026, at which time the Company will need to secure additional funding. If the Company is unable to obtain additional financing, the lack of liquidity could have a material adverse effect on the Company’s future prospects.   The accompanying condensed unaudited interim financial statements have been prepared on a goin … tes include fair value of the Company’s convertible promissory notes, the grant date fair value of stock options (Note 8), the allocation of transaction price as it relates to the Company's DRL Development Agreement, and accrued research and development expenses.   Fair value of financial instruments   Management believes that the
Coya Therapeutics - Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update Skip to main content Skip to main content Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analyst Coverage Financials SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Composition Resources Information Request Form Investor Email Alerts Investor Contacts News Details Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analyst Coverage … et medical needs. Announced U.S. FDA acceptance of Investigation New Drug (IND) Application for COYA 302 for the treatment of frontotemporal dementia (FTD). Reported results of the investigator-initiated study of low-dose IL-2 and CTLA4-Ig combination treatment demonstrating Treg enhancement and cognitive stability in FTD patients. Announced $11.1 million private placement, led by Dr. Reddy’s Laboratories, Inc. ($10 million) and Greenlight Capital ($1.1 million), an existing
ALS Clinical Trials and Research | Coya Therapeutics (NASDAQ: COYA) announced that its Phase 2 clinical trial for COYA 302 in ALS patients has been accepted as a NEALS-Affiliated Trial ...
%PDF-1.4 %���� 1 0 obj > endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj [ /Separation/PANTONE#20158#20C/DeviceCMYK 5 0 R ] endobj 5 0 obj > stream H�$����Z����l,�Z-��j���Uk-��l۶m��~¾w�=�E��i�V4O�h1N?#�S�D�3JR��,E��Y��e9�\��T��H�J���gQ�JV�\5�W/\�F֤b-*����\'�rV=���Tm���֘�M�)5�Q�y�Z-�%g���9ٚ:m�-u�Q��lO�ّ�ѰSv���م�٤kv�i��A��4i�'�Ҳ ������h=�6C � ��h7�sG�Hڏ��tCDZ9����:M��'��d� s*ݦ�t�Ϡ�̜E��9�^s�}Q^L�y9�� �0ѿ�b,a��\Ơ�y �W0de�b� [��1|M^Έ��\��Up�72fSnf��ʸm�ߞ;��3w1q7���^.ؗ���S�A. ���i.{�5��s\�|�/���|��/�+lx�����lz��o�[ly;�a�l{/�g��w|�Ώ�cv}����3�|�_�����}_�������� ��C��O�3G~����~� … /2Q== Acrobat Distiller 8.0.0 (Macintosh) Current Opionion ED-BOARD.indd imac-4 application/postscript saved xmp.iid:FB7F1174072068118F62F5F62AD105BC 2011-12-01T10:41:14+05:30 Adobe Illustrator CS4 / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:45CDCACE1C2068118F62F5F62AD105BC 2011-12-01T11:12:20+05:30 Adobe Illustrator CS4 / converted from application/postsc … 11:12:20+05:30 Adobe Illustrator CS4 / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:3C7803BE3E2068118F62F5F62AD105BC 2011-12-01T15:01:14+05:30 Adobe Illustrator CS4 / xmp.iid:45CDCACE1C2068118F62F5F62AD105BC xmp.did:45CDCACE1C2068118F62F5F62AD105BC uuid:5a7c0b52-f53d-9e44-adad-2c3db2986c15 uuid:5a7c0b52-f53d-9e44-adad-2c3db2986c15 xmp.iid:3C7803BE3E2068118F62F5F62AD105BC xmp.did:3C7803BE3E2068118F62F5F62AD105BC True False 1 639.4492
Coya Therapeutics - Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results Skip to main content Skip to main content Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analyst Coverage Financials SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Composition Resources Information Request Form Investor Email Alerts Investor Contacts News Details Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analys … c investment by the Alzheimer’s Drug Discovery Foundation (ADDF) that will help fund the development of COYA 302 for the treatment of FTD. The ADDF is aligned with our belief in the value of combination therapies for neurodegenerative diseases. We are evaluating plans for advancing COYA 302 in FTD into clinical trials. “In addition, in April, Dr. Stanley Appel Chairman of our Scientific Advisory Board, presented data in patients with ALS that correlates biomarker 4-HNE with t … didates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates,
Coya Therapeutics - Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS) Skip to main content Skip to main content Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analyst Coverage Financials SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Composition Resources Information Request Form Investor Email Alerts Inves … ent to Coya. Upon the first FDA acceptance of an investigational new drug (IND) application for COYA 302 for the treatment of ALS, Dr. Reddy’s will pay Coya an additional USD 4.2 million. Upon dosing of the first patient in the first Phase 2 trial of COYA 302 for the treatment of ALS in the United States, Dr. Reddy’s will pay Coya an additional USD 4.2 million. Coya anticipates that the IND filing will be made in the first half of 2024. The Agreement also includes development … travenous routes, for global markets. Dr. Reddy’s proposed rituximab biosimilar application has been accepted for review by the USFDA, EMA and MHRA. Coya has also ramped up manufacturing capacity to support its global expansion plans. About Dr. Reddy’s Laboratories Limited: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, it is committed to providin … didates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates,
Coya Therapeutics - Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Skip to main content Skip to main content Overview News Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Analyst Coverage Financials SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Composition Resources Information Request Form Investor Email Alerts Investor Contacts News Details Overview News Events & Prese … didates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates,
Houston biotech company developing multiple Treg-based therapies Skip to content Home About Us Clinical Trials Science & Technology Pipeline Investor Relations Resources Patient Resources Contact Unleashing the Power of Tregs Multiple Treg therapeutic modalities addressing neurodegenerative, autoimmune, and metabolic diseases Learn MOre We are a clinical-stage company focused on developing our multi-modality Treg therapies for neurodegenerative , autoimmune , and metabolic diseases . Strong proof of concept data in Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s Treg Enhancing B
Business of Biotech podcast: COYA 302 for #ALS treatment | Coya Therapeutics, Inc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign
Raven.config('https://[email protected]/147999').install(); Play it back: Houston therapeutics co. sees momentum with expanded treatment opportunities - InnovationMap X Startups Tech Health Energy Impact Money Lifestyle Space Sports Featured Innovators Guest Columns Houston Voices Houston Innovation Awards Promoted Advertise Subscribe INNOVATIONMAP EMAILS ARE AWESOME Sign up now About Us Advertise Submit a Story Terms of Use Privacy Policy Startups Tech Health Energy Impact Money Lifestyle Space Sports Featured Innovators Guest Columns Houston Voices Houston Innovation